OPKO Health (NASDAQ:OPK) Earns Neutral Rating from Analysts at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. began coverage on shares of OPKO Health (NASDAQ:OPK - Get Free Report) in a report released on Friday, Marketbeat reports. The brokerage set a "neutral" rating on the biotechnology company's stock.

Several other research firms also recently weighed in on OPK. StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd. HC Wainwright restated a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. Finally, Barrington Research restated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, OPKO Health currently has an average rating of "Moderate Buy" and a consensus target price of $2.75.

OPKO Health Price Performance

Shares of NASDAQ OPK traded down $0.03 during mid-day trading on Friday, reaching $1.37. The company's stock had a trading volume of 663,849 shares, compared to its average volume of 3,877,671. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a 52 week low of $1.15 and a 52 week high of $2.04. The stock has a fifty day moving average of $1.63 and a two-hundred day moving average of $1.57. The firm has a market capitalization of $920.02 million, a PE ratio of -7.21 and a beta of 1.78.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. As a group, sell-side analysts anticipate that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock in a transaction on Monday, March 17th. The shares were acquired at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the completion of the purchase, the chief executive officer now directly owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 767,434 shares of company stock worth $1,238,312 over the last three months. 49.69% of the stock is owned by insiders.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently bought and sold shares of OPK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of OPKO Health by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company's stock valued at $275,000 after buying an additional 8,064 shares during the period. Two Sigma Advisers LP increased its stake in shares of OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company's stock valued at $560,000 after buying an additional 8,396 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares during the period. Comerica Bank increased its stake in shares of OPKO Health by 18.2% during the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company's stock valued at $156,000 after buying an additional 16,369 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of OPKO Health by 4.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company's stock valued at $670,000 after buying an additional 18,571 shares during the period. Hedge funds and other institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.